Negalstobart

奈加苏拜单抗

Report date: 2023/12/29 11:51:30

Base Information

Drug NameNegalstobart
Drug Alias Name重组全人源抗淋巴细胞活化基因3（LAG-3）单克隆抗体IBI-110
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitors
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsSkin MelanomaSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaGermany +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesThe First Affiliated Hospital Of Zhengzhou UniversityFudan UniversityInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesInnovent Biologics (Usa), Inc
Active IndicationsSmall Cell Lung CarcinomaHematologic NeoplasmsHead and Neck Neoplasms +[7] 
Inactive IndicationsSkin MelanomaCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A